START

San Antonio, Texas 78229

4 studies enrolling now · 14 studies all time

What they study most

Advanced Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Advanced HR+/HER2- Breast Cancer, Advanced Solid Tumor, Advanced Solid Tumors, Advanced or Metastatic Solid Tumors, Biliary Tract Cancer, Bladder Cancer, Cancer, Cancer Metastatic, Cancer, Malignant Tumors, Carcinoma

Studies at this site

• Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors — Recruiting now
• Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors — Recruiting now
• Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors — Recruiting now
• An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors — Recruiting now
• A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies — Recruiting now
• Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors — Running, not enrolling
• Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors — Completed
• Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors — Completed
• A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies — Completed
• Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors — Stopped early
• Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors — Status unconfirmed
• Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors — Stopped early
• Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient — NO_LONGER_AVAILABLE
• A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma — Completed